Vandortuzumab vedotin

Drug Profile

Vandortuzumab vedotin

Alternative Names: Anti-STEAP1-vc-MMAE; DSTP-3086S; RG-7450

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; STEAP1 protein inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 01 Jan 2016 Genentech completes a phase-I clinical trials in Prostate cancer in USA (IV) (NCT01283373)
  • 19 Oct 2015 Phase-I development is ongoing in USA for Prostate cancer in USA
  • 02 Jun 2013 Preliminary adverse events data from a phase I trial in Prostate cancer presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top